ClinicalTrials.gg

Program

pimurutamab

Also written as “HLX07”, “HLX43+HLX07” and “HLX43 DOSE 2 + HLX10 + HLX07”.

In Fosun Pharma's pipeline, pimurutamab. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colonic Neoplasms · Nasopharyngeal Carcinoma · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Adenosquamous, led by 2 companies.

Furthest: phase 3, since Jan 4, 202617 company-led studies, 8 open or runningNext primary completion: Jul 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma168 open or runningphase 3since Jan 4, 2026Jun 11, 2018Jul 28, 2027phase 2 · NCT07358585
Henlix10 open or runningphase 1since Dec 27, 2015Dec 27, 2015none ahead
  • Named in Fosun Pharma’s own pipeline as HLX07 (pimurutamab), phase 2, as of Sep 21, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 27, 2015First study: phase 1 study in Neoplasm MetastasisNew to HenlixHenlix · NCT02648490 · 19 enrolled · United States, Taiwan
  2. Jun 11, 2018Fosun Pharma's first study: phase 2 study in Advanced Solid TumorsNew to Fosun PharmaFosun Pharma · NCT03577704 · 56 enrolled · China
  3. Mar 2, 2020Phase 2 study in Squamous Cell Carcinoma of Head and NeckFosun Pharma · NCT04297995 · 131 enrolled · China
  4. Jul 20, 2021Phase 2 study in Squamous Non-small-cell Lung CancerFosun Pharma · NCT04976647 · 156 enrolled · China
  5. Jan 18, 20222 phase 2 studiesFosun Pharma · NCT05215925, NCT05221658
  6. Feb 7, 20223 phase 2 studiesFosun Pharma · NCT05239650, NCT05238363, NCT05246982
  7. Mar 7, 2022Phase 2 study in Advanced Hepatocellular CarcinomaFosun Pharma · NCT05290220 · 60 enrolled
  8. Apr 26, 2022Phase 1 study in Solid TumorFosun Pharma · NCT05360368 · 24 enrolled · China
  9. Apr 26, 2022Phase 2 study in Small Cell Lung CarcinomaFosun Pharma · NCT05354700 · 20 enrolled · China
  10. Aug 18, 2022Phase 2 study in Nasopharyngeal Carcinoma by AJCC V8 StageFosun Pharma · NCT05513573 · 75 enrolled · China
  11. Feb 27, 2025Phase 2 study in Carcinoma of Head and/or NeckFosun Pharma · NCT06857279 · 167 planned · China
  12. Jan 4, 2026Phase 3 study in Squamous NSCLCPhase 3 reachedFosun Pharma · NCT07318883 · 720 planned · China
  13. Jan 14, 2026Phase 2 study in Colonic NeoplasmsFosun Pharma · NCT07358585 · 126 planned · China
  14. Mar 5, 2026Phase 3 study in Advanced or Metastatic Squamous Non-Small Cell Lung CancerFosun Pharma · NCT07459751 · 706 planned · China

Ahead

  1. Jul 28, 2027Primary completion: phase 2 study in Colonic NeoplasmsFosun Pharma · NCT07358585
  2. Dec 30, 2027Primary completion: phase 2 study in Carcinoma of Head and/or NeckFosun Pharma · NCT06857279
  3. Jan 15, 2030Primary completion: phase 3 study in Advanced or Metastatic Squamous Non-Small Cell Lung CancerFosun Pharma · NCT07459751
  4. Jan 2031Primary completion: phase 3 study in Squamous NSCLCFosun Pharma · NCT07318883

TargetBeta

“pimurutamab”the company's pipeline, read by Claude · source
“A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activa…”NCIt, read by Claude
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07459751Advanced or Metastatic Squamous Non-Small Cell Lung Cancer · China3RecruitingFosun PharmaJan 15, 2030706
NCT07358585Colonic Neoplasms · China2Not yet recruitingFosun PharmaJul 28, 2027126
NCT07318883Squamous NSCLC · China3Not yet recruitingFosun PharmaJan 2031720
NCT06857279Carcinoma of Head and/or Neck · China2RecruitingFosun PharmaDec 30, 2027167
NCT05513573Nasopharyngeal Carcinoma by AJCC V8 Stage · China2Active, not recruitingFosun PharmaSep 30, 202475
NCT05360368Solid Tumor · China1UNKNOWNFosun PharmaDec 30, 202324
NCT05354700Small Cell Lung Carcinoma · China2UNKNOWNFosun PharmaMar 29, 202420
NCT05290220Advanced Hepatocellular Carcinoma2UNKNOWNFosun PharmaDec 15, 202360
NCT05246982Stomach Neoplasms · China2UNKNOWNFosun PharmaDec 20, 202340
NCT05239650CRC2Not yet recruitingFosun PharmaOct 15, 202550
NCT05238363Cutaneous Squamous Cell Carcinoma · China2UNKNOWNFosun PharmaMay 15, 202320
NCT05221658ESCC or Esophageal Adenosquamous Carcinoma · China2RecruitingFosun PharmaJun 30, 202460
NCT05215925HLX07, nsqNSCLC, High EGFR Expression · China2UNKNOWNFosun PharmaJul 15, 202360
NCT04976647Squamous Non-small-cell Lung Cancer · China2UNKNOWNFosun PharmaJan 30, 2023156
NCT04297995Squamous Cell Carcinoma of Head and Neck · China2Active, not recruitingFosun PharmaMay 30, 2024131
NCT03577704Advanced Solid Tumors · China2CompletedFosun PharmaSep 30, 202256
NCT02648490Neoplasm Metastasis · United States, Taiwan1CompletedHenlixJun 28, 201919

How it is read

Names in the registry

  • “HLX07”, 12 entries
  • “HLX43+HLX07”, 1 entry
  • “HLX43 DOSE 2 + HLX10 + HLX07”, 1 entry
  • “HLX43 DOSE 3 + HLX10 + HLX07”, 1 entry
  • “HLX43 dose 1 + HLX07”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.